Stock STOK STOKE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Stoke Therapeutics, Inc.

Equities

STOK

US86150R1077

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
12.05 USD +3.43% Intraday chart for Stoke Therapeutics, Inc. -5.64% +129.09%
Apr. 17 Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer CI
Mar. 28 Sector Update: Health Care Stocks Advance Premarket Thursday MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
BU
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
CI
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
BU
Sector Update: Health Care Stocks Advance Premarket Thursday
MT
Stoke Therapeutics Prices Upsized $125 Million Share Offering
MT
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
BU
North American Morning Briefing : Stocks Edge -2-
DJ
Stoke Therapeutics Plans $75 Million Public Offering
MT
Stoke Therapeutics Announces Proposed Public Offering
BU
Sector Update: Health Care Stocks Advance Late Afternoon
MT
Stoke Therapeutics Rises After Investigational Drug Shows Improvement in Dravet Syndrome Patients
MT
Top Midday Gainers
MT
JPMorgan Adjusts Price Target on Stoke Therapeutics to $13 From $6, Maintains Neutral Rating
MT
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading
MT
Needham Adjusts Stoke Therapeutics' Price Target to $22 From $14, Maintains Buy Rating
MT
Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $21 From $18, Keeps Buy Rating
MT
US Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence Readings
MT
Top Premarket Gainers
MT
Wedbush Adjusts Stoke Therapeutics' Price Target to $17 From $13, Keeps Outperform Rating
MT
Canaccord Genuity Adjusts Stoke Therapeutics Price Target to $21 From $18, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. STOK Stock
  4. News Stoke Therapeutics, Inc.